FDA-cleared respiratory panel providing 95% sensitivity and 99% specificity for rapid identification of respiratory pathogens and antibiotic resistance.
Our FDA-cleared respiratory panel provides an overall sensitivity of 95% and specificity of 99%. Rapid and accurate diagnostic testing for respiratory pathogens helps identify which patients to isolate and determines appropriate antibiotic or antiviral therapy.
With the increasing prevalence of antibiotic-resistant organisms and the critical need for appropriate antimicrobial stewardship, accurate and rapid respiratory pathogen identification has never been more important for optimal patient care and infection control.
FDA-cleared respiratory testing provides significant advantages for patient care
95% sensitivity and 99% specificity provide reliable results for confident clinical decision-making.
Fast turnaround time enables quick isolation decisions and appropriate therapy initiation.
Identifies antibiotic resistance markers to guide appropriate antimicrobial therapy selection.
Detects multiple bacterial and viral respiratory pathogens in a single test.
Rapid pathogen identification supports effective isolation and infection control measures.
Supports responsible antibiotic use and reduces unnecessary antimicrobial exposure.
PCR diagnostics provides valuable insights across multiple healthcare settings
People acquire serious bacterial infections that are resistant to one or more prescribed antibiotics annually in the US
People die as a direct result of antibiotic resistant infections each year
Of antibiotic prescriptions for Acute Respiratory Tract Infections are unnecessary
The misuse of antibiotics costs the US healthcare system over $20 billion each year.
Our multiplex PCR respiratory panel detects bacterial and viral respiratory pathogens
Nasopharyngeal swab or respiratory specimen
Multiplex real-time PCR detection
Clinical interpretation and recommendations
Rapid electronic reporting
References:
8- CDC. Antibiotic Resistance Threats in the United States, 2013.
9- Steinman MA et al. JAMA. 2003;289(6):719-725. Predictors of Broad-Spectrum Antibiotic Prescribing for Acute Respiratory Tract Infections in Adult Primary Care
10- Alliance for Prudent Use of Antibiotics; Cost of antibiotic resistance to U.S. families and the health care system.
Get accurate respiratory pathogen identification with our FDA-cleared testing panel.